This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Read more »Advanced Cell receives green light from independent monitoring board to move forward with US trials
Advanced Cell Technology (OTCBB:ACTC) has received approval to move forward with enrolling and treating the next set of patients.
Read more »Editor’s Note October 3, 2011
As OneMedForum SF 2012 approaches, OneMedSentinel is on the lookout for some of the most promising companies and technologies, as […]
Read more »Sector Reports on Investment Opportunities in Health and Medicine Featured at 5th Annual OneMedForum
OneMedPlace announced today that OneMedForum San Francisco 2012 will feature special reports in 8 healthcare sectors.
Read more »The Wallace H. Coulter Foundation Optimizes Academia Process
“We have very clear timelines, milestones, and we define the critical experiment that, if it’s successful will bring value to the technology and make it ready for follow-up funding.”
Read more »Vasomedical Proves Itself A Company To Watch On The Fast Track to Growth
With the recent acquisition of the two Chinese companies, restructuring, and the addition of a new CFO, Vasomedical is now positioned to move forward and further implement plans for expansion and growth.
Read more »This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Read more »NeoStem Expected To Have Short and Long Term Value Drivers
NeoStem has transformed itself over the last year and half with two acquisitions, multiple financings and their expansion into China.
Read more »Citigroup Pricing The Offering of GSVC [NASDAQ:GSVC] Later This Week
Citigroup [NYSE:CITI] pricing GSVC’s $100 million raise this week. As of end of trading Sept 19th, GSVC stock is trading at about $14.37 and seems undervalued for several reasons.
Read more »Editor’s Note September 19, 2011
OneMedSentinel is pleased to bring you another round of stories and interviews with some of the most promising companies and […]
Read more »